Synapse - Thoracic Oncology

Results (3394)

Real-world evaluation of consolidative durvalumab in locally advanced non-small-cell lung cancer treated with definitive chemoradiation

Meeting Abstract

Shaverdian, N.; Zhang, Z.; Lobaugh, S.; Deasy, J. O.; Offin, M.; Preeshagul, I.; Hellmann, M. D.; Chaft, J.; Shepherd, A. F.; Gelblum, D.; more...
International Journal of Radiation Oncology, Biology, Physics (2019)

Fulltext@MSK | Save

Predicting tumor progression in early stage non-small cell lung cancer using pre-treatment imaging

Meeting Abstract

Thor, M.; Fitzgerald, K. J.; Iyer, A.; Apte, A.; Oh, J. H.; Chaft, J.; Wu, A. J.; Offin, M.; Gelblum, D.; Deasy, J. O.; more...
International Journal of Radiation Oncology, Biology, Physics (2019)

Fulltext@MSK | Save

Central review of contours and treatment plans for hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) - Implementation and lessons learned from a prospective multicenter phase II study

Meeting Abstract

Yorke, E. D.; Kuo, L.; Cho, J.; Mak, R. H.; Garces, Y.; Perez, B. A.; Gomez, D. R.; Fontenla, S.; Czmielewski, C.; McKnight, D.; more...
International Journal of Radiation Oncology, Biology, Physics (2019)

Fulltext@MSK | Save

NTRK fusion detection across three assays and 29,000 tumors

Meeting Abstract

Solomon, J.; Sireci, N.; Drilon, A.; Mullaney, K.; Benayed, R.; Ladanyi, M.; Hechtman, J.
Modern Pathology (2019)

Fulltext@MSK | Save

Evaluation of H3K27me3 expression as a marker of EZH2 activation in SMARCA4/SMARCA2-deficient tumors and candidate biomarker for trials of EZH2 inhibitors

Meeting Abstract

Kezlarian, B.; Montecalvo, J.; Sauter, J.; Travis, W.; Gounder, M.; Rudin, C.; Ladanyi, M.; Namakydoust, A.; Rekhtman, N.
Modern Pathology (2019)

Fulltext@MSK | Save

Acute lung injury pattern is a frequent histologic finding in lung tissue following immune checkpoint inhibitor therapy

Meeting Abstract

Golden, A.; Imran, S.; Feinstein, M.; Hellmann, M.; Plodkowski, A.; Rekhtman, N.; Rizvi, H.; Travis, W.; Stover, D.; Sauter, J.
Modern Pathology (2019)

Fulltext@MSK | Save

Importance of distinguishing adenocarcinoma and squamous cell carcinoma in assessment of pathologic response after neoadjuvant chemotherapy

Meeting Abstract

Emoto, K.; Qu, Y.; Zheng, H.; Aly, R.; Eguchi, T.; Chaft, J.; Tan, K. S.; Kris, M.; Adusumilli, P.; Travis, W.
Modern Pathology (2019)

Fulltext@MSK | Save

Genomic profiling of prostate cancer with EGFR family gene alterations-potential of clinical and therapeutic implications

Meeting Abstract

Momeni Boroujeni, A.; Gupta, S.; Li, B.; Al-Ahmadie, H.; Solit, D.; Reuter, V.; Gopalan, A.; Arcila, M.; Fine, S.; Ladanyi, M.; more...
Modern Pathology (2019)

Fulltext@MSK | Save

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Journal Article

Schoenfeld, A. J.; Arbour, K. C.; Rizvi, H.; Iqbal, A. N.; Gadgeel, S. M.; Girshman, J.; Kris, M. G.; Riely, G. J.; Yu, H. A.; Hellmann, M. D.
Annals of Oncology (2019)

Fulltext@MSK | Save

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): Updated results, including overall survival, from PROFILE 1001

Journal Article

Shaw, A. T.; Riely, G. J.; Bang, Y. J.; Kim, D. W.; Camidge, D. R.; Solomon, B. J.; Varella-Garcia, M.; Iafrate, A. J.; Shapiro, G. I.; Usari, T.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save